Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Arizona

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Concerns

For decades, public health communication has centered on broad wellness principles and the dissemination of general medical knowledge. This legacy framework prioritized accessible information about disease prevention, nutrition, and common ailments, serving as a foundation for informed patient decision-making. Within this context, audiences became accustomed to understanding health risks in population-level terms, often without direct reference to specific therapeutic interventions or their potential long-term consequences. As medical science advanced, the focus shifted from general awareness to the nuanced realities of specialized treatments. One such area involves biologic therapies used in chronic autoimmune conditions, where patient exposure to certain medications introduces distinct risk profiles. In particular, the administration of Tysabri (natalizumab) has been associated with a rare but serious opportunistic infection of the central nervous system. This transition from general health literacy to a more targeted concern requires careful navigation, as individuals who have received this therapy may now face questions about delayed adverse effects. The pivot from broad health education to occupational or legal consideration emerges when patients or their families seek accountability for harm allegedly linked to pharmaceutical exposure. In Arizona, the statute of limitations governs the timeframe for filing claims related to such exposure. This legal parameter transforms a clinical risk into a practical concern, demanding that affected individuals act within a defined period to preserve their rights. Thus, the legacy of general health information now converges with the specific need to understand time-sensitive legal recourse following Tysabri use and the potential development of progressive multifocal leukoencephalopathy.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and the boxed warning emphasizes that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must also be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Risk Factors for PML

The clinical presentation of PML can be subtle and variable, often including progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. In the FDA Adverse Event Reporting System (FAERS), adverse events most frequently associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and depression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with those of multiple sclerosis itself, which can delay recognition of PML. The boxed warning instructs healthcare professionals to monitor patients and withhold Tysabri immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can reactivate latent JC virus in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination. The risk is highest in patients who are anti-JCV antibody positive, have been on therapy for more than two years, or have previously used immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The timeline between exposure and documented harm can vary from months to years, with longer treatment duration increasing risk.

Legal Considerations for Arizona Patients: Statute of Limitations

For patients in Arizona who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability claim. In Arizona, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. Given that PML symptoms may initially be mistaken for multiple sclerosis relapse, the discovery date can be complex. Affected patients or their families should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances. Key factors include the adequacy of warnings provided by the manufacturer and healthcare providers about PML risk, the patient's adherence to the TOUCH program requirements, and the timeline between Tysabri initiation and PML diagnosis. The adequacy of warnings is a central issue. The boxed warning clearly states that Tysabri increases PML risk and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, patients and prescribers must be fully informed about the magnitude of risk and the need for vigilant monitoring. If a patient was not adequately counseled about PML symptoms or the importance of regular JCV antibody testing, this could form the basis of a claim. Additionally, the TOUCH program is designed to ensure informed consent and risk mitigation, but any lapses in program implementation could be relevant. In summary, Tysabri carries a well-documented risk of PML, with specific risk factors and a mandated monitoring program. Patients in Arizona who have suffered PML should be aware of the statute of limitations and seek legal advice promptly. The medical evidence underscores the importance of early recognition and immediate discontinuation of Tysabri at the first sign of PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Arizona?

In Arizona, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, which may initially be mistaken for multiple sclerosis relapse, the discovery date can be complex. It is crucial to consult with an attorney promptly to preserve your rights.

What are the known risk factors for developing PML while on Tysabri?

Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when assessing individual risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.